The U.S. hemostats market size is expected to reach US$ 1.8 billion in 2026 and US$ 2.8 billion growing at a CAGR of 6.5% between 2026 and 2033. This sustained growth trajectory is primarily driven by increasing surgical procedure volumes across cardiovascular, orthopedic, and general surgery specialties, supported by the expanding aging population and rising prevalence of chronic diseases necessitating surgical intervention.

The aging U.S. demographic, projected to exceed 21% of the total population by 2030 according to the U.S. Census Bureau,s combined with growing adoption of advanced active hemostats and combination hemostat products in complex surgical environments, is reinforcing consistent market expansion across hospital and ambulatory surgical care settings nationwide.

Drivers - Rising U.S. Surgical Procedure Volumes and Demand for Advanced Hemostasis

The rising volume of surgical procedures performed annually across the United States is a fundamental and structural demand driver for the hemostats market. According to the American Hospital Association (AHA), over 51 million inpatient and outpatient surgeries are performed in the United States each year, with cardiovascular, orthopedic, and general surgery collectively accounting for the largest proportion of procedure volumes. The American Academy of Orthopaedic Surgeons (AAOS) reports that over 900,000 total knee and hip replacement surgeries are performed annually in the U.S., each requiring reliable intraoperative hemostasis management. Simultaneously, the American Heart Association (AHA) estimates that approximately 395,000 open-heart surgeries are conducted annually in the United States, where fibrin sealants and thrombin-based hemostats are essential intraoperative tools, sustaining consistent demand for premium hemostat products.

Aging U.S. Population and Growing Burden of Cardiovascular and Orthopedic Disease

The accelerating aging of the U.S. population is creating a durable and structural demand increase for hemostatic products across surgical specialties. According to the U.S. Census Bureau, the population aged 65 years and older is projected to reach approximately 80 million by 2040, directly driving higher surgical procedure rates for cardiovascular, orthopedic, and oncological conditions that require advanced hemostasis management. The Centers for Disease Control and Prevention (CDC) reports that heart disease remains the leading cause of death in the United States, affecting over 697,000 Americans annually. Furthermore, the CDC estimates that more than 37 million Americans are living with diabetes a condition associated with impaired hemostasis and elevated perioperative bleeding risk increasing clinical reliance on advanced active and combination hemostat products to achieve reliable surgical bleeding control.

Market Restraints - Stringent FDA Regulatory Pathways and Extended Approval Timelines

The U.S. Food and Drug Administration (FDA) requires rigorous clinical evidence for hemostat approvals through 510(k) premarket notification or Premarket Approval (PMA) pathways, creating meaningful barriers for new market entrants. The average 510(k) review timeline is approximately 150 days, while PMA applications can extend to 2-3 years with mandatory clinical trial investment. Biologically based hemostats including thrombin formulations and fibrin sealants face additional scrutiny under FDA biologics regulations administered by the Center for Biologics Evaluation and Research (CBER), significantly increasing time-to-market and development costs for innovative hemostat technologies.

Pricing Pressure from Group Purchasing Organizations and Value-Based Care Models

Advanced hemostat products, particularly fibrin sealants and combination hemostatic agents carry premium pricing that faces significant headwinds within the U.S. hospital cost-containment environment. Hospital group purchasing organizations (GPOs), which negotiate procurement contracts for approximately 98% of U.S. hospitals according to the Healthcare Supply Chain Association (HSCA), exert substantial downward pricing pressure on surgical product suppliers. Declining Medicare and Medicaid reimbursement rates for surgical procedures have further incentivized hospital systems to standardize lower-cost passive hemostat alternatives, particularly in outpatient and ambulatory surgical settings, constraining premium product adoption.

Opportunities - Combination Hemostats Emerging as the Fastest Growing Product Segment

Combination hemostats which integrate active (thrombin-based) and passive (collagen or gelatin-based) components to achieve synergistic hemostatic efficacy represent the fastest growing product segment in the U.S. hemostats market. By engaging multiple coagulation pathways simultaneously, these advanced formulations deliver faster, more reliable hemostasis in high-risk surgical procedures including cardiovascular, neurosurgical, and complex orthopedic reconstructions.

Clinical evidence published in the Journal of the American College of Surgeons has demonstrated that combination hemostats significantly reduce intraoperative blood loss and allogenic transfusion requirements compared to single-component alternatives. Companies including Johnson & Johnson Services, Inc. (Ethicon) and Baxter International Inc. are actively advancing next-generation combination hemostat platforms, and their sustained R&D pipeline investments signal strong product category growth through the forecast period.

Ambulatory Surgical Centers (ASCs) as a High-Growth End-User Opportunity

The rapid expansion of Ambulatory Surgical Centers (ASCs) across the United States represents a significant and growing commercial opportunity for hemostat manufacturers. According to the Ambulatory Surgery Center Association (ASCA), over 6,100 Medicare-certified ASCs operate nationwide, collectively performing approximately 60% of all U.S. outpatient surgical procedures. Centers for Medicare & Medicaid Services (CMS) policy changes continue to shift an increasing number of procedures including orthopedic, spine, and select cardiovascular interventions from hospital inpatient settings to ASC environments, creating strong demand for user-friendly, cost-effective, and ready-to-use hemostat formulations designed for outpatient surgical workflows. Manufacturers investing in compact, single-use, and simplified-application hemostat product designs are well-positioned to capture this rapidly expanding end-user demand.

Product Type Insights

Active hemostats command 39% of the U.S. hemostats market in 2026, establishing them as the dominant product segment. This leadership reflects the superior hemostatic efficacy of thrombin-based hemostats and fibrin sealants, which directly activate the coagulation cascade to achieve rapid and reliable bleeding control in complex, high-acuity surgical procedures. Thrombin-based products including bovine thrombin, human pooled thrombin, and recombinant human thrombin formulations are widely deployed across cardiovascular, neurosurgical, and orthopedic surgery settings. The FDA has approved multiple active hemostat products from leading manufacturers including Johnson & Johnson Services, Inc. (Ethicon), Baxter International Inc., and Pfizer Inc. Clinical practice guidelines from the American College of Surgeons endorse active hemostats for high-volume surgical bleeding scenarios, reinforcing their clinical utility and segment dominance.

Application Insights

Cardiovascular surgery is the leading application segment in the U.S. hemostats market, commanding approximately 32% of total market revenue in 2026. This leadership reflects the high volume and complexity of cardiac and vascular surgical procedures performed annually in the United States, where rapid and reliable intraoperative hemostasis is clinically critical.

According to the American Heart Association (AHA), nearly 395,000 open-heart surgeries and over 400,000 coronary artery bypass grafting (CABG) procedures are performed in the U.S. each year. Cardiovascular surgeries involve systemic anticoagulation and extensive tissue manipulation, creating significant demand for both active and combination hemostat products. Leading manufacturers including Baxter International Inc. and Johnson & Johnson (Ethicon) maintain purpose-built cardiovascular hemostat product portfolios sustaining consistent segment demand.

Zone-wise Insights

Southeast U.S. Hemostats Market Trends and Insights

The Southeast U.S. accounted for 29% of the U.S. hemostats market revenue in 2026, maintaining its leadership through a combination of high surgical volumes, an expanding elderly population, and a significant burden of cardiovascular, orthopedic, and trauma-related procedures. States including Florida, Georgia, and North Carolina host extensive hospital networks, Level I trauma centers, and leading academic medical institutions that drive consistent demand for advanced hemostatic products. Rising obesity and diabetes prevalence contribute to increasing vascular and general surgeries, while ongoing healthcare infrastructure expansion and strong adoption of minimally invasive surgical techniques continue to support robust utilization of surgical hemostats across the region.

Southwest U.S. Hemostats Market Trends and Insights

The Southwest U.S. represented approximately 18% of the U.S. hemostats market revenue in 2026, supported by rapid population growth, expanding healthcare infrastructure, and increasing surgical demand across Texas, Arizona, and New Mexico. The region benefits from a growing number of ambulatory surgery centers, large integrated hospital systems, and rising investments in specialty care services. High incidences of trauma, cancer, and chronic diseases requiring surgical intervention continue to fuel demand for advanced hemostatic agents. Additionally, increasing adoption of minimally invasive and robotic-assisted surgeries, coupled with expanding access to healthcare in fast-growing metropolitan areas, is expected to strengthen long-term market growth.

The U.S. hemostats market exhibits a consolidated competitive structure, with market leaders Johnson & Johnson Services, Inc. (Ethicon), Baxter International Inc., Pfizer Inc., and Medtronic plc collectively commanding significant combined revenue through comprehensive product portfolios spanning active, passive, and combination hemostat categories. Key competitive differentiators include product hemostatic efficacy, ease of intraoperative application, breadth of FDA-cleared product lines, and established GPO contracting relationships. Emerging competitive trends reflect increasing R&D investment in next-generation combination hemostats, bioabsorbable platforms, and minimally invasive application systems. Specialty players including Integra LifeSciences Corporation and Gelita Medical GmbH differentiate through targeted surgical niche applications and specialized biomaterial expertise.

Key Developments:

• In April 2026, Xtant Medical Holdings, Inc. announced that it had entered into an exclusive U.S. distribution agreement with Dilon Technologies, Inc. for the HEMOBLAST® Bellows hemostatic powder. Under the agreement, Xtant Medical became the exclusive distributor of the product across the United States, expanding its portfolio of surgical solutions for spine, orthopedic, and trauma procedures.
• In April 2025, Teleflex received FDA 510(k) clearance to expand the indications for its QuikClot Control+™ hemostatic device to include all grades of internal and external bleeding, from mild to life-threatening, across multiple anatomical sites.
• In October 2024, Johnson & Johnson Services, Inc. announced the availability of VISTASEAL in the U.S. market, expanding its portfolio of advanced hemostatic products.